BioEP™ - decision support that unlocks the full potential of EEG with mathematical modelling
BioEP uses the power of mathematical modelling to unlock the greater potential of EEG by increasing its diagnostic yield. BioEP analyses EEG for the presence of data features and brain network based markers that are shown to be elevated in people with epilepsy. BioEP is UKCA marked.
For more details on the mathematics behind BioEP or our scientific publications underpinning BioEP, take a look at our Impacts & Insights.
What is BioEP™ and how does it work?
- A clinical decision support system:
BioEP analyses EEG data to determine if the analysis supports epilepsy or suggests a differential diagnosis.
- Utilises routine EEG recordings and returns an indication of supportiveness for epilepsy:
Clinicians upload anonymised EEG data to the BioEP platform. Within 15 minutes a BioEP report is generated.
- Digital biomarkers for epilepsy:
Detects brain network-based markers (biomarkers) shown in published research to be altered in people with epilepsy.
- Supports clinicians:
Provides an additional layer of evidence to assist with diagnosis and decisions about the next steps. It can be applied in ‘live’ clinical practise and retrospectively to a baclkog of inconclusive EEGs waiting for follow-up.
BioEP™ regulatory compliance
BioEP is a Class 1 Medical Device under 93/42/EEC Medical Device Directive (MDD) and is UKCA marked. Neuronostics are Cyber Essentials certified and registered with ISO for data protection.
An overview of BioEP™ solutions
Available in the UK Available Internationally
In Development
BioEP™ for diagnosis
Designed to support clinicians in diagnosing epilepsy in adult seizure clinics, BioEP provides objective insights to enhance decision-making.
Additionally, BioEP for diagnosis can be applied retrospectively to existing EEG data, making it a valuable support tool for tackling backlog cases and prioritizing patient care more efficiently.
BioEP™ for clinical trials
Designed to enhance the efficiency of clinical trials for new therapeutics by:
- Identifying optimal patient cohorts;
- Providing bespoke EEG analysis;
- Detecting patient subgroups most responsive to treatment.
BioEP™ for paediatrics
We have been contracted by Nottingham Universities NHS Trust to develop and validate BioEP for children aged 2-18. Our current OASIS trial is assessing its effectiveness in paediatric epilepsy diagnosis.
BioEP™ for prognosis
Early findings suggest that BioEP may assess the effectiveness of anti-epileptic treatments. Our current ECLIPSE trial is investigating its potential for treatment guidance and personalised epilepsy management.